Hengrui Medicine: Caspofungin Acetate for Injection passed the consistency evaluation of generic drugs

On May 31, Hengrui Medicine stated that it had recently received the "Drug Supplementary Application Approval Notice" on caspofungin acetate for injection approved and issued by the National Medical Products Administration.

This product is suitable for adult patients and pediatric patients (three months and more):

Empirical treatment of suspicious fungal infections in patients with neutropenia and fever; treatment of candidiasis and the following Candida infections: abdominal abscess, peritonitis, and pleural infection; treatment of esophageal candidiasis; treatment ineffective or ineffective with other treatments Tolerant of invasive aspergillosis.

Caspofungin is a echinocandin that can inhibit the synthesis of β(1,3)-D-glucan, the basic component of the cell wall of susceptible Aspergillus and Candida.

Caspofungin acetate for injection was originally developed by MERCK, and was approved by the US Food and Drug Administration in 2001 to be marketed in the United States under the trade name Cancidas.

Upon inquiry, the global sales of caspofungin-related dosage forms in 2020 will be approximately US$454 million.

According to relevant national policies and regulations, appropriate support should be given to medical insurance payment for drug varieties that have passed the consistency evaluation of generic drugs, and medical institutions should give priority to procurement and give priority to selection in clinical practice.

According to the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized Drug Purchases" (Guobanfa [2021] No.